Cegedim (ALCGM.PA) Stock Price

Cegedim Price

Euronext·CLOSED
10.68EUR+0.58 (+5.58 %)
Market closed

Over the last 19 years Cegedim grew revenue by 1.0% annually, reaching 649.17 M EUR. Earnings per share have declined at 17.7% per year over the last 10 years. For Cegedim, the net margin of 1.4% is down versus 5.0% a few years ago. At today's price the dividend yield works out to roughly 4.68%. The payout ratio is around 50% of earnings. The consensus 12-month price target for Cegedim is 13.26 EUR, about 24.2% above where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 20% above its 52-week low.

Cegedim stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Cegedim over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cegedim stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cegedim's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Cegedim Stock Price History
DateCegedim Price
8/4/202610.68 EUR
7/31/202610.10 EUR
7/30/202610.06 EUR
7/29/202610.12 EUR
7/28/202610.20 EUR
7/27/202610.14 EUR
7/24/202610.10 EUR
7/23/202610.16 EUR
7/22/202610.12 EUR
7/21/202610.10 EUR
7/20/202610.04 EUR
7/17/202610.24 EUR
7/16/202610.30 EUR
7/15/202610.24 EUR
7/14/202610.34 EUR
7/13/202610.32 EUR
7/10/202610.46 EUR
7/9/202610.46 EUR
7/8/202610.52 EUR
7/7/202610.50 EUR
7/6/202610.40 EUR
7/3/202610.58 EUR
7/2/202610.48 EUR
7/1/202610.38 EUR
6/30/202610.70 EUR
6/29/202610.86 EUR
6/26/202611.04 EUR
6/25/202611.20 EUR
6/24/202611.04 EUR
6/23/202611.40 EUR
6/22/202611.50 EUR
6/19/202611.46 EUR
6/18/202611.40 EUR
6/17/202611.60 EUR
6/16/202611.38 EUR
6/15/202611.46 EUR
6/12/202611.26 EUR
6/11/202611.26 EUR
6/10/202611.26 EUR
6/9/202611.18 EUR
6/8/202611.08 EUR
6/5/202611.40 EUR
6/4/202611.52 EUR
6/3/202611.42 EUR
6/2/202611.40 EUR
6/1/202611.46 EUR
5/29/202611.60 EUR
5/28/202611.70 EUR
5/27/202611.86 EUR
5/26/202611.40 EUR
5/25/202611.40 EUR
5/22/202611.54 EUR
5/21/202611.50 EUR
5/20/202611.58 EUR
5/19/202610.90 EUR
5/18/202610.80 EUR
5/15/202611.00 EUR
5/14/202610.76 EUR
5/13/202610.72 EUR
5/12/202610.90 EUR
5/11/202610.80 EUR
5/8/202611.00 EUR
5/7/202610.96 EUR
5/6/202610.82 EUR
5/5/202610.82 EUR
5/4/202611.50 EUR
4/30/202612.00 EUR
4/29/202611.90 EUR
4/28/202611.65 EUR
4/27/202611.65 EUR
4/24/202612.30 EUR
4/23/202612.15 EUR
4/22/202612.15 EUR
4/21/202612.10 EUR
4/20/202612.40 EUR
4/17/202612.50 EUR
4/16/202612.40 EUR
4/15/202612.50 EUR
4/14/202612.20 EUR
4/13/202612.65 EUR
4/10/202613.10 EUR
4/9/202613.70 EUR
4/8/202613.25 EUR
4/7/202612.38 EUR
4/2/202612.16 EUR
3/27/202610.85 EUR
3/26/202610.00 EUR
3/25/20269.64 EUR
3/24/20269.80 EUR
3/23/20268.90 EUR
3/20/20269.10 EUR
3/19/20269.54 EUR
3/18/20269.38 EUR
3/17/20269.44 EUR
3/16/20269.98 EUR
3/13/202610.50 EUR
3/12/202610.50 EUR
3/11/202610.50 EUR
3/10/202610.10 EUR
3/9/202610.05 EUR
3/6/202610.15 EUR
3/5/202610.10 EUR
3/4/202610.50 EUR
3/3/202610.40 EUR
3/2/202610.85 EUR
2/27/202610.70 EUR
2/26/202611.80 EUR
2/25/202611.55 EUR
2/24/202611.85 EUR
2/23/202612.05 EUR
2/20/202611.90 EUR
2/19/202612.00 EUR
2/18/202612.25 EUR
2/17/202612.50 EUR
2/16/202612.95 EUR
2/13/202613.00 EUR
2/12/202612.80 EUR
2/11/202613.15 EUR
2/10/202613.15 EUR
2/9/202612.95 EUR
2/6/202612.70 EUR
2/5/202613.25 EUR
2/4/202613.30 EUR
2/3/202613.25 EUR
2/2/202613.35 EUR
1/30/202613.35 EUR
1/29/202613.80 EUR
1/28/202613.75 EUR
1/27/202613.75 EUR
1/26/202613.75 EUR
1/23/202613.75 EUR
1/22/202613.75 EUR
1/21/202613.60 EUR
1/20/202613.70 EUR
1/19/202613.55 EUR
1/16/202613.75 EUR
1/15/202613.80 EUR
1/14/202613.65 EUR
1/13/202613.60 EUR
1/12/202613.45 EUR
1/9/202613.60 EUR
1/8/202613.75 EUR
1/7/202613.85 EUR
1/6/202614.35 EUR
1/5/202614.15 EUR
1/2/202613.85 EUR
12/31/202513.55 EUR
12/30/202513.50 EUR
12/29/202513.60 EUR
12/24/202513.35 EUR
12/23/202513.30 EUR
12/22/202513.30 EUR
12/19/202513.35 EUR
12/18/202513.40 EUR
12/17/202513.30 EUR
12/16/202513.35 EUR
12/15/202513.25 EUR
12/12/202513.25 EUR
12/11/202513.30 EUR
12/10/202513.20 EUR
12/9/202513.25 EUR
12/8/202513.35 EUR
12/5/202513.30 EUR
12/4/202513.30 EUR
12/3/202513.35 EUR
12/2/202513.30 EUR
12/1/202513.15 EUR
11/28/202513.15 EUR
11/27/202513.15 EUR
11/26/202513.05 EUR
11/25/202512.85 EUR
11/24/202512.75 EUR
11/21/202512.50 EUR
11/20/202512.50 EUR
11/19/202512.00 EUR
11/18/202511.85 EUR
11/17/202512.15 EUR
11/14/202512.05 EUR
11/13/202512.10 EUR
11/12/202512.10 EUR
11/11/202512.35 EUR
11/10/202511.50 EUR
11/7/202511.50 EUR
11/6/202511.65 EUR
11/5/202511.50 EUR
11/4/202511.75 EUR
11/3/202511.75 EUR
10/31/202511.40 EUR
10/30/202511.50 EUR
10/29/202511.70 EUR
10/28/202511.80 EUR
10/27/202511.75 EUR
10/24/202512.30 EUR
10/23/202511.40 EUR
10/22/202511.30 EUR
10/21/202511.20 EUR
10/20/202510.80 EUR
10/17/202510.80 EUR
10/16/202510.80 EUR
10/15/202510.70 EUR
10/14/202510.60 EUR
10/13/202510.40 EUR
10/10/202510.50 EUR
10/9/202510.55 EUR
10/8/202510.60 EUR
10/7/202510.65 EUR
10/6/202510.60 EUR
10/3/202511.00 EUR
10/2/202511.20 EUR
10/1/202511.70 EUR
9/30/202510.75 EUR
9/29/202510.95 EUR
9/26/202510.60 EUR
9/25/202510.25 EUR
9/24/202510.20 EUR
9/23/202510.10 EUR
9/22/202510.05 EUR
9/19/202510.00 EUR
9/18/202510.00 EUR
9/17/20259.98 EUR
9/16/20259.94 EUR
9/15/202510.20 EUR
9/12/202510.20 EUR
9/11/202510.25 EUR
9/10/202510.15 EUR
9/9/202510.25 EUR
9/8/202510.40 EUR
9/5/202510.45 EUR
9/4/202510.50 EUR
9/3/202510.40 EUR
9/2/202510.60 EUR
9/1/202510.60 EUR
8/29/202510.65 EUR
8/28/202510.75 EUR
8/27/202510.65 EUR
8/26/202510.65 EUR
8/25/202510.65 EUR
8/22/202510.80 EUR
8/21/202510.65 EUR
8/20/202510.45 EUR
8/19/202510.70 EUR
8/18/202510.75 EUR
8/15/202510.65 EUR
8/14/202510.60 EUR
8/13/202510.60 EUR
8/12/202510.65 EUR
8/11/202510.65 EUR
8/8/202510.70 EUR
8/7/202510.50 EUR
8/6/202510.45 EUR
Access this data via the Eulerpool API
Get Free API Key

Cegedim Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
524.71 M EUR
43.69 M EUR
26.22 M EUR
Jan 1, 2022
555.21 M EUR
26.49 M EUR
13.62 M EUR
Jan 1, 2023
616.00 M EUR
18.37 M EUR
-7.41 M EUR
Jan 1, 2024
654.50 M EUR
11.09 M EUR
-14.71 M EUR
Jan 1, 2025
649.17 M EUR
30.24 M EUR
9.40 M EUR
Jan 1, 2026 (e)
659.55 M EUR
33.01 M EUR
29.74 M EUR
Jan 1, 2027 (e)
684.05 M EUR
34.05 M EUR
36.48 M EUR
Jan 1, 2028 (e)
703.00 M EUR
35.14 M EUR
33.18 M EUR

Cegedim Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 4:07 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
902.00493.00426.00440.00457.00467.00503.00496.00524.00555.00615.00654.00649.00659.00684.00702.00
-2.06-45.34-13.593.293.862.197.71-1.395.655.9210.816.34-0.761.543.792.63
93.1381.5490.6192.2792.5693.7994.4394.9695.0495.1441.4695.4120.6520.6520.6520.65
840.00402.00386.00406.00423.00438.00475.00471.00498.00528.00255.00624.00134.00136.06141.23144.94
25.0038.0041.002.0018.0014.0048.0021.0043.0026.0018.0011.0030.0033.0034.0035.00
2.777.719.620.453.943.009.544.238.214.682.931.684.625.014.974.99
-58.00-199.0066.00-26.0011.005.002.0010.0026.0013.00-7.00-14.009.0029.0036.0033.00
-31.76243.10-133.17-139.39-142.31-54.55-60.00400.00160.00-50.00-153.85100.00-164.29222.2224.14-8.33
–––––––––0.50–––0.500.500.50
––––––––––––––––
13.9513.9814.0313.9713.9813.9013.8613.8213.7713.6313.5613.7013.7713.7713.7713.77
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Cegedim generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cegedim retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cegedim's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Cegedim has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cegedim's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Cegedim stock margins

The Cegedim margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cegedim. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cegedim.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
94.91 %
8.33 %
5.00 %
Jan 1, 2022
95.22 %
4.77 %
2.45 %
Jan 1, 2023
41.50 %
2.98 %
-1.20 %
Jan 1, 2024
95.48 %
1.69 %
-2.25 %
Jan 1, 2025
20.78 %
4.66 %
1.45 %
Jan 1, 2026 (e)
20.78 %
5.00 %
4.51 %
Jan 1, 2027 (e)
20.78 %
4.98 %
5.33 %
Jan 1, 2028 (e)
20.78 %
5.00 %
4.72 %

Cegedim Stock Revenue, EBIT, Earnings per Share

The Cegedim earnings per share therefore indicates how much revenue Cegedim has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
38.11 EUR
3.17 EUR
1.90 EUR
Jan 1, 2022
40.73 EUR
1.94 EUR
1.00 EUR
Jan 1, 2023
45.42 EUR
1.35 EUR
-0.55 EUR
Jan 1, 2024
47.79 EUR
0.81 EUR
-1.07 EUR
Jan 1, 2025
47.15 EUR
2.20 EUR
0.68 EUR
Jan 1, 2026 (e)
46.78 EUR
2.40 EUR
2.11 EUR
Jan 1, 2027 (e)
48.51 EUR
2.47 EUR
2.59 EUR
Jan 1, 2028 (e)
49.86 EUR
2.55 EUR
2.35 EUR

Cegedim business model & stock analysis

Cegedim SA is a French company that was founded in 1969. It has since become one of the leading providers of IT solutions for the healthcare industry worldwide. Headquartered in Boulogne-Billancourt, France, the company operates in over 80 countries and employs over 4,000 employees. The business model of Cegedim is focused on improving the efficiency and effectiveness of healthcare providers. To do this, the company offers a wide range of products and services based on IT solutions and digital technologies. These are designed to help doctors, pharmacists, hospitals, insurance companies, and other stakeholders in the healthcare industry improve their workflows and optimize patient care. One of the company's key divisions is the Cegedim Health Data Division, which specializes in the collection, analysis, and processing of health data. This includes databases and analyses of medication prescriptions and medical care pathways. This information provides valuable insights into the market and helps healthcare providers identify trends. In addition, Cegedim offers a wide range of IT solutions for the healthcare industry, including e-health platforms, medical practice software, electronic patient records, and insurance billing systems. One of Cegedim's particular strengths is its experience in data analysis. The company has a broad expertise and years of experience in this field. An example of this is the Cegedim IRIS Index, which enables healthcare providers to assess the effectiveness of their medical care. This tool provides cost-optimized and patient-centered analysis and is, therefore, an important part of the Cegedim product line. Cegedim also works closely with health authorities, hospitals, universities, and other stakeholders to develop innovative ideas and solutions. The company is a member of numerous industry organizations, including the European Health Telematics Association (EHTEL) and the Healthcare Information and Management Systems Society (HIMSS). Cegedim's product range is diverse to meet the different needs of healthcare providers. These include: - PMD, a medical practice software that enables efficient management of practice processes and patient data. - Mobile Health Solutions, which allows doctors and nurses to access patient data and medical information from mobile devices. - Medication Insights, a tool for analyzing medication prescriptions that provides valuable insights into the market for healthcare providers and pharmaceutical companies. Cegedim also relies on strategic partnerships to improve the reach and performance of its products and services. One example of this is the partnership with Salesforce, which leads to the development of joint solutions to support doctors and other healthcare professionals. Overall, Cegedim has established itself as one of the leading companies in the healthcare industry, leveraging innovative technologies and data analysis to help its customers work more effectively and efficiently.

Cegedim SWOT Analysis

Strengths

Cegedim SA possesses several strengths that contribute to its success and competitive advantage. These include:

  • Strong market presence: Cegedim SA holds a prominent position in the [insert industry/sector] industry.
  • Extensive product and service offering: The company offers a diverse range of products and services, catering to the various needs of its customers.
  • Technological expertise: Cegedim SA demonstrates advanced technological capabilities, allowing for innovative solutions and efficient operations.
  • Established customer base: The company has a loyal and expanding customer base, which provides a reliable revenue stream.

Weaknesses

Despite its strengths, Cegedim SA also faces certain weaknesses that could impede its growth and performance. These include:

  • Dependency on key clients: The company relies heavily on a few major clients for a significant portion of its revenue, making it vulnerable to any shifts in those clients' businesses.
  • Limited geographical presence: Cegedim SA may have limited market reach in certain regions, hindering its potential for expansion.
  • Lack of diversification: The company's product/service portfolio may be too concentrated in a particular area, making it susceptible to market disruptions or changing customer demands.
  • High competition: Cegedim SA operates in a highly competitive market, where rivals with similar offerings may pose a threat to its market share and profitability.

Opportunities

Cegedim SA can leverage a range of opportunities to further enhance its business prospects. These include:

  • Market expansion: The company can explore untapped markets or invest in strategic partnerships to extend its reach and capture new customers.
  • Technology advancements: Cegedim SA can capitalize on emerging technologies, such as artificial intelligence and big data analytics, to develop innovative solutions for its target market.
  • Industry growth: The [insert industry/sector] industry is projected to experience steady growth, presenting opportunities for Cegedim SA to increase its market share.
  • Acquisition or mergers: The company can consider strategic acquisitions or mergers with complementary businesses to strengthen its product offering and gain a competitive edge.

Threats

Cegedim SA faces certain threats that may pose challenges to its operations and profitability. These threats include:

  • Economic downturns: Changes in global or regional economic conditions can impact customer spending habits and potentially reduce demand for Cegedim SA's products and services.
  • Regulatory changes: Developments in regulations, particularly in the healthcare or technology sectors, can impose compliance burdens or restrict certain operations.
  • New market entrants: The industry may witness the entry of new competitors, potentially intensifying competition and eroding Cegedim SA's market position.
  • Technological disruptions: Rapid advancements in technology can render existing solutions obsolete, necessitating continuous innovation and adaptation by Cegedim SA.

Cegedim Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Cegedim historical P/E ratio, EBIT multiple, and P/S ratio

Cegedim annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Cegedim shares outstanding

The number of shares of Cegedim was 13.77 M in 2025. This indicates how many shares Cegedim is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
13.77 M Stocks
Jan 1, 2022
13.63 M Stocks
Jan 1, 2023
13.56 M Stocks
Jan 1, 2024
13.70 M Stocks
Jan 1, 2025
13.77 M Stocks
Jan 1, 2026 (e)
13.77 M Stocks
Jan 1, 2027 (e)
13.77 M Stocks
Jan 1, 2028 (e)
13.77 M Stocks

Cegedim Dividend History

16 years of dividend payments

YearAnnual DividendYoY ChangePayments
20220.50EUR↓ 50.0%1×
20111.00EUR 0.0%1×
20101.00EUR↑ 11.1%1×
20080.90EUR↑ 12.5%1×
20070.80EUR↑ 3.9%1×
20060.77EUR↑ 13.2%1×
20050.68EUR↓ 16.0%1×
20040.81EUR 0.0%1×
20030.81EUR 0.0%1×
20020.81EUR↑ 18.1%1×

Cegedim dividend payout ratio

In 2025, Cegedim had a payout ratio of 50.03%. The payout ratio indicates the percentage of the company's profits that Cegedim distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
50.03 %
Jan 1, 2022
50.03 %
Jan 1, 2023
50.03 %
Jan 1, 2024
50.03 %
Jan 1, 2025
50.03 %
Jan 1, 2026 (e)
23.71 %
Jan 1, 2027 (e)
19.32 %
Jan 1, 2028 (e)
21.25 %

Current Cegedim forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
55.56 % (5)
Sell
44.44 % (4)
12M Price Target
13.26
Last Price
10.68
Currency
EUR
12M Return Potential
24.16 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Cegedim stock

59/100
75
Environment
87
Social
16
Governance
E

Environment

20
Scope 1 - Direct Emissions3,121
Scope 2 - Indirect emissions from purchased energy940
Scope 3 - Indirect emissions within the value chain43,926
Total CO₂ emissions4,061
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cegedim shareholder structure

% Name
0.92199%
HC Capital Advisors GmbH
HC Capital Advisors GmbH
0.71948%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.18440%
Umweltbank AG
Umweltbank AG
0.17435%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.
0.11348%
HMG Finance S.A.
HMG Finance S.A.
0.06535%
Mercer Global Investments Management Ltd
Mercer Global Investments Management Ltd

Cegedim Beneficial Ownership Filings (SEC 13D/G)

Free Float
34.6%
Float Shares
-
Shares Outstanding
-

Cegedim Executives and Management Board

11 members · avg. age 68 · 36 % women

PM

Mr. Pierre Marucchi

Deputy Managing Director, Director - Representative of FCB · since 1989

432,117.00 EUR

Management

LL

Mr. Laurent Labrune

Deputy Managing Director, Executive Director

421,274.00 EUR
JL

Mr. Jean-Claude Labrune

Chairman of the Board, Chief Executive Officer, Executive Director · since 1969

271,400.00 EUR
DB

Mr. Damien Buffet

Head of Financial Communications · since 2024

–

Board of Directors

MK

Mr. Marcel Kahn (68)

Non-Executive Independent Director

25,000.00 EUR
JC

Mr. Jean - Pierre Cassan

Non-Executive Independent Director

18,000.00 EUR
CA

Ms. Catherine Abiven

Non-Executive Director

14,000.00 EUR
SD

Ms. Sandrine Debroise

Non-Executive Director

14,000.00 EUR
AL

Ms. Aude Labrune-Marysse

Non-Executive Director

14,000.00 EUR
BS

Ms. Beatrice Saunier

Non-Executive Independent Director

14,000.00 EUR

Frequently asked questions about Cegedim

Cegedim SA is a global technology and services company serving the healthcare industry. Its business model revolves around providing innovative solutions and services to healthcare professionals, pharmaceutical companies, and other stakeholders. Cegedim SA offers a wide range of products, including patient data management systems, electronic health records, pharmacy management software, and marketing solutions. Through its comprehensive portfolio, Cegedim SA enables better patient care, drives operational efficiency, and facilitates collaboration within the healthcare ecosystem. With years of expertise and a strong focus on technology-driven solutions, Cegedim SA continues to play a crucial role in transforming and improving healthcare worldwide.

Cegedim SA is primarily active in the healthcare and technology industries.

The main competitors of Cegedim SA in the market include IBM, Cerner Corporation, and Allscripts Healthcare Solutions.

Cegedim SA, a leading technology and services company, has a rich history and background. Established in 1969, Cegedim initially focused on providing innovative software solutions for healthcare professionals. Over the years, it expanded its offerings to pharmaceutical companies, insurance providers, and other healthcare stakeholders. Today, Cegedim is a global organization, operating in over 70 countries and serving more than 420,000 users. The company's strong commitment to research and development has allowed it to stay at the forefront of digital transformation in the healthcare industry. Cegedim SA's expertise and comprehensive portfolio make it a trusted partner for businesses seeking innovative and efficient healthcare solutions.

Cegedim SA, a renowned company, has achieved several significant milestones throughout its existence. It has successfully positioned itself as a global leader in innovative technology and services for the healthcare industry. Over the years, Cegedim SA has shown exceptional growth and development, expanding its presence across multiple continents. The company has established fruitful partnerships with key industry players and consistently delivers cutting-edge solutions to optimize healthcare practices. Cegedim SA's dedication to excellence and commitment to meeting evolving market demands have propelled them to become a trusted and respected name in the healthcare sector.

Cegedim SA is primarily present in various countries and regions worldwide. With its headquarters in France, the company has established a strong presence in Europe, particularly in countries like Germany, Italy, Spain, and the United Kingdom. Additionally, Cegedim SA operates in North America, with a significant presence in the United States and Canada. Furthermore, the company has expanded its reach to other regions, including Asia Pacific and Latin America. This global presence allows Cegedim SA to cater to a diverse range of clients and leverage its expertise in healthcare and technology solutions on an international scale.

Cegedim SA represents a set of core values and a strong corporate philosophy. The company is committed to excellence, innovation, and client satisfaction. With a focus on technological advancements and healthcare solutions, Cegedim SA strives to provide cutting-edge products and services. They prioritize integrity, transparency, and collaboration, aiming to build strong, trust-based relationships with their clients and partners. Cegedim SA's dedication to continuous improvement and customer-centricity drives their success in the dynamic stock market. This French-based company's values and philosophy define their approach to business and reinforce their position as a leading player in the industry.

Analysts currently set an average price target of 12.92 EUR for the Cegedim stock (median: 13.26 EUR), implying +21.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Cegedim Analyst Price Targets 2026

9 analysts currently rate the Cegedim stock: 0 recommend buying, 5 holding and 4 selling. For 2026, analysts expect Cegedim to generate revenue of 659.55 M EUR and earnings per share of 2.16 EUR.

Cegedim Analyst Price Targets 2026

The Cegedim share (ALCGM.PA) is listed on 7 stock exchanges, including: Frankfurt (C7E.F), München (C7E.MU), Düsseldorf (C7E.DU), London (0DYQ.L), London (0DYQ.L), Paris (CGM.PA).

Cegedim SA is a leading company in the healthcare industry that offers innovative technologies and services for medical record management, insurance claims processing, and the pharmaceutical industry. The company operates in various sectors, including Cegedim Health Data, Cegedim e-business, Cegedim Insurance Solutions, and Cegedim Strategic Data. Cegedim Health Data provides specialized solutions for managing medical patient data and interoperability within the healthcare industry. Cegedim e-business offers electronic transaction services and software platforms for businesses in the healthcare industry. Cegedim Insurance Solutions provides high-quality IT services for the health and accident insurance industry. Cegedim Strategic Data specializes in collecting and processing market data for the pharmaceutical and healthcare industries. In addition to these business sectors, Cegedim SA also offers specialized products and solutions. Their business model is focused on supporting healthcare industry customers to work efficiently and effectively by providing them with technology and data solutions.

The expected revenue of Cegedim is 659.55 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cegedim is 29.74 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cegedim is currently 4.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cegedim stock.

The price-to-sales ratio (P/S) of Cegedim is currently 0.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cegedim stock.

The Eulerpool Quality Score for Cegedim is 3/10.

The ISIN of Cegedim is FR0000053506. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cegedim is 895036. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cegedim is ALCGM.PA. The ticker symbol is used to trade Cegedim shares on the stock exchange.

Over the past 12 months, Cegedim paid a dividend of 0.50 EUR . This corresponds to a dividend yield of about 4.68 %. For the coming 12 months, Cegedim is expected to pay a dividend of 0.50 EUR.

The current dividend yield of Cegedim is 4.68 %.

Cegedim pays a dividend, distributed in the months of , , , .

Cegedim paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.50 EUR are expected. This corresponds to a dividend yield of 4.95 %.

Cegedim is assigned to the 'Health' sector.

To receive the latest dividend of Cegedim from amounting to 0.5 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Cegedim are distributed in EUR.

All fundamentals and in-depth analysis of Cegedim

Our stock analysis for Cegedim stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cegedim. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Cegedim Stock
Cegedim Revenue→
Cegedim Stock
Cegedim Net Income→
Cegedim Stock
Cegedim P/E→
Cegedim Stock
Cegedim P/S→
Cegedim Stock
Cegedim EBIT→
Cegedim Stock
Cegedim Dividend→
Cegedim Stock
Cegedim Directors Dealings→
Cegedim Stock
Cegedim Stocks→
Cegedim Stock
Cegedim Market capitalization→
Cegedim Stock
Cegedim Debt→
Cegedim Stock
Cegedim Liabilities→
Cegedim Stock
Cegedim Equity→
Cegedim Stock
Cegedim AAQS→
Cegedim Stock
Cegedim Employees→
Cegedim Stock
Cegedim ROE→
Cegedim Stock
Cegedim ROA→
Cegedim Stock
Cegedim ROCE→
Cegedim Stock
Cegedim News→
Cegedim Stock
Cegedim Analyst Price Targets→

Health Stocks

CEL-SCICedar CoCelcuityCeCorsCelemicsCE Holdings CoCelestraCDT EquityCell Biotech CocbdMDCell SourceCatheter PrecisionAll Stocks A–Z →